Results 71 to 80 of about 19,741 (164)

Avoidance of MAIT cells is an essential determinant of <i>Listeria</i> monocytogenes pathogenesis. [PDF]

Proc Natl Acad Sci U S A
Rivera-Lugo R, Garcia Castillo J, Lobanovska M, Tang E, Anaya-Sanchez A, Espich S, Stanley SA, DuPage M, Portnoy DA.   +8 more
europepmc   +1 more source

Cardiovascular delivery of drugs and biotherapeutics [PDF]

Drug Delivery and Translational Research, 2018
Michael Chorny, Robert J. Levy, Gershon Golomb   +2 more
openaire   +2 more sources

Host methylglyoxal activates the <i>Listeria</i> virulence program, allowing bacteria to evade inflammatory phagocytes by cell-to-cell spread. [PDF]

Proc Natl Acad Sci U S A
Anaya-Sanchez A, Ragunathan PT, Hung A, Van Alst AJ, Lobanovska M, Stanley SA, Portnoy DA.   +6 more
europepmc   +1 more source

Bioanalysis of Biotherapeutics

Journal of Analytical & Bioanalytical Techniques, 2013
openaire   +2 more sources

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). [PDF]

Pediatr Dermatol
Eichenfield LF, Gonzalez ME, Boguniewicz M, Funk T, Hebert AA, Prajapati VH, Kindred C, Serrao R, Swanson L, Krupa D, Snyder S, Seal MS, Hanna D, Burnett P, Berk DR.   +14 more
europepmc   +1 more source

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Peters S, Piha-Paul SA, Sehgal K, Calvo E, Bockorny B, Galvao V, Dowlati A, Fontana E, Hernandez-Guerrero T, Rivera Herrero F, Kingsley E, Lopez JS, Patnaik A, Perez CA, Sanborn RE, Knowles S, Patilea-Vrana G, Li J, Wang T, Wang Y, Hollebecque A.   +20 more
europepmc   +1 more source

Correction. [PDF]

Gut Microbes
europepmc   +1 more source

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. [PDF]

Orphanet J Rare Dis
Holida M, Linhart A, Longo N, Wallace E, Tøndel C, Hughes D, Warnock DG, Pisani A, Eyskens F, Deegan P, Feldt-Rasmussen U, Goker-Alpan O, Mehta A, Piotti G, Fichera V, Wang M, Chertkoff R, Waldek S, Wilcox WR, Bernat JA.   +19 more
europepmc   +1 more source

Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers. [PDF]

Lung Cancer
Zhou N, Tsui S, Toumbacaris N, Tan KS, Dycoco J, Chidi AP, Gray KD, Sihag S, Park BJ, Bott MJ, Adusumilli PS, Molena D, Rusch VW, Huang J, Bains MS, Rocco G, Isbell JM, Jones DR.   +17 more
europepmc   +1 more source

From association to causation: a decision-aware framework for reproducible biomarker discovery and precision intervention design in the human gut microbiome. [PDF]

Brief Bioinform
Ascandari A, Aminu S, Benhida R, Rachid D.   +3 more
europepmc   +1 more source